Aaron Yarlas1, Mary Kaye Willian2, Arpita Nag3,4. 1. QualityMetric, 1301 Atwood Avenue, Suite 216E, Johnston, RI, 02919, USA. ayarlas@qualitymetric.com. 2. Shire, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA. 3. Shire, 300 Shire Way, Lexington, MA, 02421, USA. 4. Sanofi, 270 Albany St, Cambridge, MA, 02139, USA.
Abstract
PURPOSE: Studies of patients with ulcerative colitis (UC) report that reduced clinical symptoms and endoscopic activity predict better health-related quality of life (HRQoL). However, no study has examined the joint and unique associations of clinical and endoscopic activity with HRQoL, nor of histologic inflammation and HRQoL. These post hoc analyses evaluated whether reduced clinical, endoscopic, and histologic disease activity were uniquely associated with improved HRQoL for adults with active mild-to-moderate UC receiving once-daily 4.8 g/day multimatrix mesalazine for 8 weeks. METHODS: Assessments at baseline and week 8 (i.e., treatment completion) included clinical and endoscopic activity (modified UC-Disease Activity Index), histology (Geboes scoring), and HRQoL (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]; SF-12v2® Health Survey [SF-12v2]). Associations among each type of disease activity and HRQoL were examined by correlations and by mean changes in SIBDQ and SF-12v2 scores between disease activity subgroups (e.g., achievement of clinical remission; mucosal healing). Regression models estimated unique variance in HRQoL accounted by each type of disease activity. RESULTS: Within the analysis sample (n = 717), patients with reduced clinical and endoscopic activity had significantly larger improvements in all HRQoL domains (p < 0.001), as did patients in both endoscopic and clinical remission compared to patients in endoscopic remission only (p < 0.05). Patients with histologic activity post-treatment scored significantly worse on all HRQoL domains than patients with no activity (p < 0.05). Correlations and regression models found that decreases in clinical and endoscopic activity were associated with improvements in HRQoL domain scores. CONCLUSIONS: Clinical symptoms and mucosal health have separable, distinct impacts on UC patients' HRQoL.
PURPOSE: Studies of patients with ulcerative colitis (UC) report that reduced clinical symptoms and endoscopic activity predict better health-related quality of life (HRQoL). However, no study has examined the joint and unique associations of clinical and endoscopic activity with HRQoL, nor of histologic inflammation and HRQoL. These post hoc analyses evaluated whether reduced clinical, endoscopic, and histologic disease activity were uniquely associated with improved HRQoL for adults with active mild-to-moderate UC receiving once-daily 4.8 g/day multimatrix mesalazine for 8 weeks. METHODS: Assessments at baseline and week 8 (i.e., treatment completion) included clinical and endoscopic activity (modified UC-Disease Activity Index), histology (Geboes scoring), and HRQoL (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]; SF-12v2® Health Survey [SF-12v2]). Associations among each type of disease activity and HRQoL were examined by correlations and by mean changes in SIBDQ and SF-12v2 scores between disease activity subgroups (e.g., achievement of clinical remission; mucosal healing). Regression models estimated unique variance in HRQoL accounted by each type of disease activity. RESULTS: Within the analysis sample (n = 717), patients with reduced clinical and endoscopic activity had significantly larger improvements in all HRQoL domains (p < 0.001), as did patients in both endoscopic and clinical remission compared to patients in endoscopic remission only (p < 0.05). Patients with histologic activity post-treatment scored significantly worse on all HRQoL domains than patients with no activity (p < 0.05). Correlations and regression models found that decreases in clinical and endoscopic activity were associated with improvements in HRQoL domain scores. CONCLUSIONS: Clinical symptoms and mucosal health have separable, distinct impacts on UC patients' HRQoL.
Entities:
Keywords:
Clinical symptoms; Endoscopy; Histology; Quality of life; Ulcerative colitis
Authors: William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar Journal: Gastroenterology Date: 2011-11-04 Impact factor: 22.682
Authors: Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn Journal: Gastroenterology Date: 2011-06-30 Impact factor: 22.682
Authors: A Bitton; M A Peppercorn; D A Antonioli; J L Niles; S Shah; A Bousvaros; B Ransil; G Wild; A Cohen; M D Edwardes; A C Stevens Journal: Gastroenterology Date: 2001-01 Impact factor: 22.682
Authors: Henrik Hjortswang; Gunnar Järnerot; Bengt Curman; Hanna Sandberg-Gertzén; Curt Tysk; Björn Blomberg; Sven Almer; Magnus Ström Journal: Eur J Gastroenterol Hepatol Date: 2003-09 Impact factor: 2.566
Authors: Aaron Yarlas; David T Rubin; Julian Panés; James O Lindsay; Séverine Vermeire; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Marco DiBonaventura Journal: J Crohns Colitis Date: 2018-04-27 Impact factor: 9.071